HCV NS3 inhibitors resistance mutations in the telaprevir started Turkish patients with chronic HCV

被引：0
|
作者：
Sayan, M. [1 ]
Akhan, S. C. [2 ]
Aygen, B. [3 ]
Koruk, S. Tekin [4 ]
Mistik, R. [5 ]
Demirturk, N. [6 ]
Ural, O. [7 ]
机构：
[1] Kocaeli Univ, Kocaeli, Izmit, Turkey
[2] Kocaeli Univ, Izmit, Kocaeli, Turkey
[3] Erciyes Univ, Sch Med, Kayseri, Turkey
[4] Harran Univ, Sanliurfa, Turkey
[5] Uludag Univ, Bursa, Turkey
[6] Afyon Kocatepe Univ, Sch Med, Afyon, Turkey
[7] Selcuk Univ, Konya, Turkey
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2014年 / 21卷
关键词：
D O I：
10.1016/j.ijid.2014.03.1367
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
64.037
引用
收藏
页码：459 / 459
页数：1
相关论文
共 50 条
  • [21] Two distinct HCV genotype 1a clades: geographical distribution and association with natural resistance mutations to HCV NS3/4A inhibitors
    De Luca, A.
    Di Giambenedetto, S.
    Prosperi, M.
    Lo Presti, A.
    Torti, C.
    Caudai, C.
    Vicenti, I.
    Saladini, F.
    Almi, P.
    Grima, P.
    Blanc, P.
    Fabbiani, M.
    Rossetti, B.
    Gagliardini, R.
    Ciccozzi, M.
    Zazzi, M.
    ANTIVIRAL THERAPY, 2013, 18 : A47 - A47
  • [22] Avoiding drug resistance against HCV NS3/4A protease inhibitors
    Romano, K.
    Ali, A.
    Schiffer, C.
    ANTIVIRAL THERAPY, 2010, 15 : A25 - A25
  • [23] Virologic Responses and Safety of the current NS3/4A Protease Inhibitors (Telaprevir and Boceprevir) in HCV Treatment-Experienced patients
    Mousa, Omar
    Pham, Ly-Elaine
    Egwim, Chukwuma I.
    Zela, Scott A.
    Ankoma-Sey, Victor
    HEPATOLOGY, 2012, 56 : 1039A - 1040A
  • [24] Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
    Angela Costantino
    Enea Spada
    Michele Equestre
    Roberto Bruni
    Elena Tritarelli
    Nicola Coppola
    Caterina Sagnelli
    Evangelista Sagnelli
    Anna Rita Ciccaglione
    Virology Journal, 12
  • [25] Mutations in the natural strains of NS3 protease domain of HCV in HIV/HCV coinfected patients under antiretroviral therapy including or not HIV protease inhibitors
    Morsica, Giulia
    Bagaglio, Sabrina
    Alagna, Laura
    Lodrini, Chiara
    Gallotta, Giulia
    Galli, Laura
    Dispinseri, Stefania
    Lazzarin, Adriano
    Uberti-Foppa, Caterina
    HEPATOLOGY, 2006, 44 (04) : 352A - 352A
  • [26] IN VITRO CHARACTERIZATION OF THE PAN-GENOTYPE ACTIVITY OF THE HCV NS3/4A PROTEASE INHIBITORS BOCEPREVIR AND TELAPREVIR
    Howe, J. A.
    Graham, D.
    McMonagle, P.
    Curry, S.
    Chase, R.
    Lahser, F.
    Ogert, R. A.
    Strizki, J.
    Barnard, R. J. B. O.
    Zhang, R.
    Zhuyan, G.
    Treitel, M.
    Hazuda, D. J.
    Howe, A. Y.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S329 - S329
  • [27] Investigation of NS3 protease resistance mutations for the prediction of treatment response to HCV triple therapy
    Dietz, J.
    Rupp, D.
    Perner, D.
    Fueller, C.
    Raeder, M.
    Susser, S.
    Zeuzem, S.
    Bartenschlager, R.
    Sarrazin, C.
    ANTIVIRAL THERAPY, 2014, 19 : A40 - A40
  • [28] QSAR and Docking Studies of HCV NS3 Serine Protease Inhibitors
    da Cunha, Elaine F. F.
    Matos, Karina S.
    Ramalho, Teodorico C.
    MEDICINAL CHEMISTRY, 2013, 9 (06) : 774 - 805
  • [29] Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients
    McCormick, Adele L.
    Moynihan, Luke
    Macartney, Malcolm J.
    Garcia-Diaz, Ana
    Smith, Colette
    Johnson, Margaret A.
    Rodger, Alison J.
    Bhagani, Sanjay
    Haque, Tanzina
    Webster, Daniel P.
    ANTIVIRAL THERAPY, 2015, 20 (03) : 361 - 363
  • [30] HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naive patients: consideration for HCV genotyping resistance testing
    Ruggiero, T.
    Burdino, E.
    Calcagno, A.
    Bonora, S.
    Boglione, L.
    Di Perri, G.
    Ghisetti, V.
    INFECTION, 2016, 44 (06) : 789 - 792
12345